BENZYDAMINE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H23N3O
Molecular Weight	309.4054
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCCOC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3

InChI

InChIKey=CNBGNNVCVSKAQZ-UHFFFAOYSA-N

InChI=1S/C19H23N3O/c1-21(2)13-8-14-23-19-17-11-6-7-12-18(17)22(20-19)15-16-9-4-3-5-10-16/h3-7,9-12H,8,13-15H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C19H23N3O
Molecular Weight	309.4054
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.oralscience.com/en/documentation/monographs/monograph-pharixia.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68001591

Benzydamine (benzydamine hydrochloride, PHARIXIA®) is a benzyl-indazole having analgesic, antipyretic, and anti-inflammatory effects. It is indicated for the relief of pain in acute sore throat and for the symptomatic relief of oro-pharyngeal mucositis caused by radiation therapy.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
prostaglandin production involved in inflammatory response 3 Target ID: GO:0002539 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4044146	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Acute sore throat 2 Sources: http://www.oralscience.com/en/documentation/monographs/monograph-pharixia.pdf	Primary		Approved 8583	PHARIXIA Approved Use PHARIXIA (benzydamine hydrochloride) is indicated for the relief of pain in acute sore throat and for the symptomatic relief of oro-pharyngeal mucositis caused by radiation therapy.
Oro-pharyngeal mucositis 2 Sources: http://www.oralscience.com/en/documentation/monographs/monograph-pharixia.pdf	Primary		Approved 8583	PHARIXIA Approved Use PHARIXIA (benzydamine hydrochloride) is indicated for the relief of pain in acute sore throat and for the symptomatic relief of oro-pharyngeal mucositis caused by radiation therapy.

C_max

Value	Dose	Analyte	Population
68 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
459 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
35 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	100 mg single, oral transmucosal dose: 100 mg route of administration: Oral transmucosal experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
546 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
14 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	100 mg single, topical dose: 100 mg route of administration: Topical experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
10 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	140 mg single, vaginal dose: 140 mg route of administration: Vaginal experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
0.8 μg/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/4044147/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
541 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4907 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
494 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	100 mg single, oral transmucosal dose: 100 mg route of administration: Oral transmucosal experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4994 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
455 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	100 mg single, topical dose: 100 mg route of administration: Topical experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
162 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	140 mg single, vaginal dose: 140 mg route of administration: Vaginal experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
60.996 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32410819/	6 mg single, vaginal dose: 6 mg route of administration: Vaginal experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
17.284 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32410819/	6 mg single, vaginal dose: 6 mg route of administration: Vaginal experiment type: SINGLE co-administered:	BENZYDAMINE N-OXIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
100.264 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32410819/	6 mg 1 times / day multiple, vaginal dose: 6 mg route of administration: Vaginal experiment type: MULTIPLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
30.477 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32410819/	6 mg 1 times / day multiple, vaginal dose: 6 mg route of administration: Vaginal experiment type: MULTIPLE co-administered:	BENZYDAMINE N-OXIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
8.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	100 mg single, oral transmucosal dose: 100 mg route of administration: Oral transmucosal experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1932611/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
13 h REVIEW https://pubmed.ncbi.nlm.nih.gov/4044147/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	BENZYDAMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
50.4 mg 1 times / day multiple, oral Studied dose Dose: 50.4 mg, 1 times / day Route: oral Route: multiple Dose: 50.4 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11972485/	unhealthy, ADOLESCENT\|ADULT Health Status: unhealthy Age Group: ADOLESCENT\|ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11972485/	Disc. AE: Urticaria, Angioedema... AEs leading to discontinuation/dose reduction: Urticaria (2.2%) Angioedema (2.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/11972485/
1.5 mg/mL 1 times / 3 hours multiple, oromucosal Recommended Dose: 1.5 mg/mL, 1 times / 3 hours Route: oromucosal Route: multiple Dose: 1.5 mg/mL, 1 times / 3 hours Sources: https://pubmed.ncbi.nlm.nih.gov/3521255/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3521255/	Disc. AE: Pain burning, Stinging... AEs leading to discontinuation/dose reduction: Pain burning Stinging Sources: https://pubmed.ncbi.nlm.nih.gov/3521255/
50 mg 3 times / day multiple, oral Studied dose Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28961427/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/28961427/	Sources: https://pubmed.ncbi.nlm.nih.gov/28961427/

AEs

AE	Significance	Dose	Population
Angioedema	2.2% Disc. AE	50.4 mg 1 times / day multiple, oral Studied dose Dose: 50.4 mg, 1 times / day Route: oral Route: multiple Dose: 50.4 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11972485/	unhealthy, ADOLESCENT\|ADULT Health Status: unhealthy Age Group: ADOLESCENT\|ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11972485/
Urticaria	2.2% Disc. AE	50.4 mg 1 times / day multiple, oral Studied dose Dose: 50.4 mg, 1 times / day Route: oral Route: multiple Dose: 50.4 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11972485/	unhealthy, ADOLESCENT\|ADULT Health Status: unhealthy Age Group: ADOLESCENT\|ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11972485/
Pain burning	Disc. AE	1.5 mg/mL 1 times / 3 hours multiple, oromucosal Recommended Dose: 1.5 mg/mL, 1 times / 3 hours Route: oromucosal Route: multiple Dose: 1.5 mg/mL, 1 times / 3 hours Sources: https://pubmed.ncbi.nlm.nih.gov/3521255/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3521255/
Stinging	Disc. AE	1.5 mg/mL 1 times / 3 hours multiple, oromucosal Recommended Dose: 1.5 mg/mL, 1 times / 3 hours Route: oromucosal Route: multiple Dose: 1.5 mg/mL, 1 times / 3 hours Sources: https://pubmed.ncbi.nlm.nih.gov/3521255/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3521255/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 substrate 1946	substrate 1193 inhibitor 2438	inhibitor 2507 substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP1A2 2153	FMO5 5 CYP1A2 1197 CYP2E1 729 CYP2A6 626 FMO3 77 FMO1 25 P-gp 2052 CYP2C19 1119 UGT 219

Drug as perpetrator

Target	Modality	Activity
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyNjEwIn19	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyNjEwIn19	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTI2MTAifX0=	no [IC50 >10 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyNjEwIn19	yes [IC50 5.0119 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTI2MTAifX0=	yes [IC50 7.9433 uM]

Drug as victim

Target	Modality	Activity
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/12555#section=BioAssay-Results Page: 5 \| 66	inconclusive
FMO3 77	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11136294/	major [Km 40.4 uM]
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11136294/	major
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11136294/	minor
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11136294/	minor
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11136294/	minor
CYP2E1 729	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11136294/	minor
UGT 219	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12228184/	minor
CYP2A6 626	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11136294/	no
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11136294/	no
FMO5 5	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11136294/	no
FMO1 25	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11136294/	yes [Km 23.6 uM]

PubMed

Title	Date	PubMed
Effect on postoperative sore throat of spraying the endotracheal tube cuff with benzydamine hydrochloride, 10% lidocaine, and 2% lidocaine.	2010-10	20304980
The development and in vitro evaluation of sustained release tablet formulations of benzydamine hydrochloride and its determination.	2010-09	20426743
[Use abusive of benzydamine in Brazil: an overview in pharmacovigilance].	2010-05	20464184
Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia.	2010-03	20184807
Lymphomatoid photocontact dermatitis to benzydamine hydrochloride.	2010-02	20136895
Thermally sensitive gels based on chitosan derivatives for the treatment of oral mucositis.	2010-02	19854272
Respiratory symptoms and inflammatory responses to Difflam throat-spray intervention in half-marathon runners: a randomised controlled trial.	2010-02	18523036
Oral rinses, mouthwashes and sprays for improving recovery following tonsillectomy.	2010-01-20	20091649
Direct electrochemistry of drug metabolizing human flavin-containing monooxygenase: electrochemical turnover of benzydamine and tamoxifen.	2010-01-20	20028087
Expression and characterization of functional dog flavin-containing monooxygenase 3.	2009-10	19635782
Recreational use of benzydamine as a hallucinogen among street youth in Brazil.	2009-09	19784487
Stevens-Johnson Syndrome triggered by chemical hair relaxer: a case report.	2009-08-05	19918477
Formulation studies of benzydamine mucoadhesive formulations for vaginal administration.	2009-07	19337872
Photopatch testing with an extended series of photoallergens: a 5-year study.	2009-06	19489967
Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial.	2009-03	19267733
Ingestions of benzydamine-containing vaginal preparations.	2009-02	18608296
Benzydamine hydrochloride buccal bioadhesive gels designed for oral ulcers: preparation, rheological, textural, mucoadhesive and release properties.	2009	19883251
[Misuse of substances theoretically without abuse potential--case series].	2009	19788132
Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: correlation with hepatic transcription factors.	2009	19571433
Relief of radiation-induced oral mucositis in head and neck cancer.	2008-12-24	19104205
Evaluation of sutures after immersion in nonalcoholic benzydamine hydrochloride mouthrinse by scanning electron microscopy.	2008-09	17994255
Antifungal effect of mouth rinses on oral Candida counts and salivary flow in treatment-naïve HIV-infected patients.	2008-08	18627277
Altered metabolism of growth hormone receptor mutant mice: a combined NMR metabonomics and microarray study.	2008-07-23	18648510
Burning mouth syndrome.	2008-03-14	19450321
Effect of different mouth rinses on third molar surgery-related oral malodor.	2008-03	18280939
Spectrophotometric determination of benzydamine HCl, levamisole HCl and mebeverine HCl through ion-pair complex formation with methyl orange.	2008-03	17625955
New pathways for alimentary mucositis.	2008	19259334
Effect of leukocyte inhibitors benzydamine and cyclophosphamide, on lung injury caused by Tityus discrepans scorpion venom.	2007-12-15	17884126
Interventions for preventing oral mucositis for patients with cancer receiving treatment.	2007-10-17	17943748
Mucocutaneous lesions of Behcet's disease.	2007-08-31	17722228
Combined photocontact dermatitis to benzydamine hydrochloride and the emulsifiers, Span 60 and Tween 60 contained in Tantum cream.	2007-07	17577365
Reduction of mouth malodour and volatile sulphur compounds in intensive care patients using an essential oil mouthwash.	2007-07	17380550
Novel hydrogels via click chemistry: synthesis and potential biomedical applications.	2007-06	17523655
Cancer treatment-induced oral mucositis.	2007-05-01	17465250
Interventions for treating oral mucositis for patients with cancer receiving treatment.	2007-04-18	17443514
[Medicine consumption and the internet: critical evaluation of a virtual community].	2007-04-05	18604400
Cytotoxicity of mouthrinses on epithelial cells by micronucleus test.	2007-04	19212481
Digital analysis of mouthrinses' staining characteristics on provisional acrylic resins.	2007-04	17371568
Effect of genetic variants of the human flavin-containing monooxygenase 3 on N- and S-oxygenation activities.	2007-03	17142560
Dexpanthenol pastille and benzydamine hydrochloride spray for the prevention of post-operative sore throat.	2007-02	17073853
[Clinical experience with tantum rosa (benzydamine hydrochloride) in prophylaxis and treatment of vaginitis and proctitis, following radiotherapy of patients with cancer of the vagina and uterus].	2007	18642555
Recreational abuse with benzydamine hydrochloride (tantum rosa).	2007	17364645
An evaluation of the efficacy of aspirin and benzydamine hydrochloride gargle for attenuating postoperative sore throat: a prospective, randomized, single-blind study.	2006-10	17000820
A pilot study of chlorhexidine and benzydamine oral rinses for the prevention and treatment of irradiation mucositis in patients with head and neck cancer.	2006-09-29	17006117
Cancer treatment-induced mucositis pain: strategies for assessment and management.	2006-09	18360600
Oral mucositis.	2006-05	16700732
Local irritant effects of topical oral sprays on oral mucosa in mice.	2006-04-29	16644611
Interventions for preventing oral mucositis for patients with cancer receiving treatment.	2006-04-19	16625538
Several therapies may prevent or reduce the severity of oral mucositis associated with cancer treatment.	2006	17187045
Benzydamine N-oxygenation as a measure of flavin-containing monooxygenase activity.	2006	16719388

Patents

Sample Use Guides

In Vivo Use Guide

Not less than 15 mL of the liquid should be used for each gargle or rinse and repeated three or four times a day, depending on the severity of the treated condition. The liquid should be kept in contact with the inflamed mucosa for at least 30 seconds and then expelled from the mouth. Administration should begin the day prior to commencement of radiation therapy and continue daily during the treatment period as well as after cessation of radiation applications until desired improvement is obtained. In acute sore throat, gargle with 15 mL every 1.5 to 3 hours. The solution should be expelled from the mouth after use.

Route of Administration: Other

In Vitro Use Guide

Benzydamine significantly reduced the basal production of both prostaglandin E2 (PGE2) and 6-keto-PGF1 alpha, the stable breakdown product of prostaglandin I2 (PGI2), in unstimulated human gingival fibroblasts. When the cells were treated simultaneously with benzydamine and the cytokines IL-1beta or TNF-alpha, the agent benzydamine reduced (P < 0.05) the stimulatory effect of IL-1beta and TNF-alpha respectively, on PGE2 and PGI2 production in human gingival fibroblasts. Furthermore, benzydamine reduced (P < 0.05) both the basal level and the cytokine-induced 3H-arachidonic acid release in gingival fibroblasts. The addition of exogenous arachidonic acid to the cells resulted in enhanced PGE2 production, which was reduced (P < 0.05) in the presence of benzydamine.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:50:54 GMT 2025` Edited by `admin` on `Mon Mar 31 17:50:54 GMT 2025`
Record UNII	4O21U048EF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

APO-BENZYDAMINE

Preferred Name

English

BENZYDAMINE

Official Name

English

Benzydamine [WHO-DD]

Common Name

English

1-BENZYL-3-(3-(DIMETHYLAMINO)PROPOXY)-1H-INDAZOLE

Systematic Name

English

1-PROPANAMINE, N,N-DIMETHYL-3-((1-(PHENYLMETHYL)-1H-INDAZOL-3-YL)OXY)-

Systematic Name

English

BENZINDAMINE

Common Name

English

benzydamine [INN]

Common Name

English

N,N-DIMETHYL-3-((1-(PHENYLMETHYL)-1H-INDAZOL-3-YL)OXY)-1-PROPANAMINE

Systematic Name

English

1-BENZYL-1H-INDAZOL-3-YL 3-(DIMETHYLAMINO)PROPYL ETHER

Systematic Name

English

BENZYDAMINE [MI]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QG02CC03